rs12053868 — IL1RAP IL1RAP amyloid risk variant

IL1RAP and the Microglial Guard Against Alzheimer's Disease

The brain's immune cells — microglia — are its primary defence against accumulating amyloid-beta plaques, the toxic protein deposits that define Alzheimer's disease. To stay activated and effective, microglia rely on a molecular on-switch: the interleukin-1 signalling complex¹¹ interleukin-1 signalling complex
IL-1 cytokine signalling is critical for microglial reactivity, phagocytosis, and amyloid clearance, which includes the receptor accessory protein encoded by IL1RAP. The rs12053868 variant sits in an intron of this gene and — through regulatory changes in expression — subtly dampens the IL-1 signal that keeps microglia primed to clear amyloid. The result is measurable: a small but steady increase in the pace at which amyloid accumulates in the aging brain.

The Mechanism

IL1RAP encodes interleukin-1 receptor accessory protein²² interleukin-1 receptor accessory protein
IL1RAP forms an obligate co-receptor with IL1R1; neither unit can transduce IL-1β or IL-1α signals alone, an essential co-receptor subunit in the IL-1 signalling complex. When IL-1β binds, the IL1R1/IL1RAP heterodimer recruits MyD88 and triggers NF-κB, driving microglial reactivity, cytokine secretion, and phagocytic activity. rs12053868 lies in intron 3 at genomic position chr3:190,582,215 (GRCh38), on the plus strand. As an intronic regulatory variant it does not change the amino acid sequence of IL1RAP; instead it appears to act as an expression quantitative trait locus³³ expression quantitative trait locus
eQTL variants alter how much of a gene's protein is produced, not its structure that mildly reduces IL1RAP transcription in microglial and neuronal cells. Lower IL1RAP levels attenuate the IL-1 signalling cascade, reducing microglial responsiveness to early amyloid deposits — allowing plaques to accumulate before the immune response clears them. Separate mouse knockout data confirms that global loss of IL-1RAcP (the IL1RAP protein) reduces pathological tau phosphorylation⁴⁴ reduces pathological tau phosphorylation
pS202 and pT231 tau epitopes are reduced in LPS-challenged Il1rap knockout mice in inflammatory contexts, underscoring the pathway's centrality to both amyloid and tau pathology.

The Evidence

The primary evidence comes from a 2015 genome-wide association study⁵⁵ 2015 genome-wide association study
Ramanan et al., ADNI cohort, longitudinal 18F-florbetapir PET imaging over 2 years published in Brain that measured longitudinal amyloid accumulation — not just amyloid burden at a single point in time, but the rate at which amyloid built up year by year. In the ADNI cohort, each G allele copy was associated with a 0.8% per-year increase in cortical amyloid standardised uptake value ratio (SUVR), reaching genome-wide significance at p = 1.38×10⁻⁹. Critically, the association held independently of APOE ε4 — the strongest known Alzheimer's genetic risk factor — establishing IL1RAP as an orthogonal risk pathway. G allele carriers also showed greater temporal-cortex atrophy on MRI, accelerated progression from mild cognitive impairment to Alzheimer's disease, and lower cortical ¹¹C-PBR28 PET signal (a marker of microglial activation), directly connecting reduced IL1RAP activity to impaired microglial surveillance.

A 2019 Swedish study⁶⁶ 2019 Swedish study
Zettergren et al., N=3,446 cases/controls, N=1,400 for CSF biomarker analyses extended these findings to CSF biomarkers. While IL1RAP variants did not significantly alter lifetime Alzheimer's disease risk in this sample, they were significantly associated with elevated CSF total-tau and phospho-tau concentrations — biomarkers of neuronal injury and tangle formation that predict disease progression. The researchers concluded that IL1RAP genetic variation influences disease intensity (how aggressively neurodegeneration proceeds) rather than merely disease susceptibility, consistent with the amyloid accumulation rate finding.

The variant's minor-allele frequency differs substantially by ancestry: ~11% in Europeans, ~14% in East Asians, but only ~2% in Africans of African descent. This pattern means the G allele's impact on population-level Alzheimer's risk is most pronounced in East Asian and European communities.

Practical Actions

No drug or supplement has been proven to specifically reverse impaired IL1RAP signalling in humans. However, because the risk mechanism runs through microglial activation and neuroinflammation⁷⁷ microglial activation and neuroinflammation
Microglia clear amyloid by phagocytosis; dampened IL-1 signalling slows this process, strategies that support microglial function and reduce chronic neuroinflammation are the most plausible targets. Long-chain omega-3 fatty acids (EPA/DHA) modulate microglial phenotype toward a more phagocytic, amyloid-clearing state. Maintaining tight control of systemic inflammatory markers (hsCRP, IL-6) reduces the chronic inflammatory background that dysregulates the very IL-1 pathway this variant affects. Monitoring cognitive biomarkers (CSF tau/amyloid, or plasma p-tau181 where available) earlier than usual can establish baseline values and flag accelerated change.

Interactions

The effect of rs12053868 is independent of APOE ε4 (rs429358 / rs7412), meaning carriers of both face compounded risk through separate biological pathways: APOE ε4 reduces direct amyloid clearance efficiency, while rs12053868-G reduces the microglial surveillance that removes plaques at the source. The CLU rs11136000 (clusterin) variant acts in the same amyloid clearance biology; individuals carrying risk alleles in both genes may have meaningfully elevated cumulative risk. IL1RAP co-variation with rs9877502 — a separate IL1RAP locus associated with CSF tau — has not yet been formally modelled but represents a plausible intra-gene interaction worth monitoring as longitudinal cohort data mature.